Allogene Therapeutics Investors

Allogene Therapeutics is a biotechnology company located in South San Francisco, California, specializing in the development of allogeneic CAR T-cell therapies for cancer treatment Founded in 2017, the company has established itself as a leader in the field of immuno-oncology Allogene Therapeutics has successfully raised significant investment totaling $288 million to advance its innovative therapeutic programs The organization collaborates with various government offices and university programs to enhance research and development efforts in cellular therapies With a strong commitment to improving patient outcomes, Allogene Therapeutics continues to drive advancements in the treatment of hematologic malignancies and solid tumors

Founded Date: 2017
Headquarters: USA
Technology: Сancer Diagnostics
Industry: FemTech
Estimated Revenue: $1M to $10M
Funding Status: IPO
Investor Type: Government Offices & University Programs